Moreover, in Kirsten rat sarcoma (KRAS)-mutated cancer upregulated TRAIL-R2 and endogenous TRAIL act in a tumour-supportive manner [43], a concept which does not seem to be limited to KRAS-mutated cancers and also engages tumour-favourable polarisation of immune cells [148]. The gene discussed is TNFRSF10B; the disease is neoplasm.